Alexion Announces Restructuring to Advance Corporate Strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Alexion Announces Restructuring to Advance Corporate Strategy
September 13, 2017 7:54 AM EDT
Deutsche Bank raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $158.00 (from $153.00) while maintaining a Buy rating following the company's restructuring announcement.
Analyst... More
September 13, 2017 6:46 AM EDT
Leerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $182.00 (from $170.00) while maintaining a Outperform rating following yesterday's reconstructing news.
Analyst Geoffrey Porges sees more good news to come, gMG Plus leverage offers upside.
...
More
September 12, 2017 1:38 PM EDT
SunTrust Robinson Humphrey analyst Yatin Suneja raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $180.00 (from $170.00) while maintaining a Buy rating after the company announced a restructuring to re-align the company with its previously announced strategic plan.
Suneja commented, "While today's... More
September 12, 2017 11:59 AM EDT
BMO Capital analyst M. Ian Somaiya raised his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $173.00 (from $168.00) while maintaining a Outperform rating as the company's plan to cut 20% of its workforce leading to $250mn annual savings was foreshadowed by prior guidance of non-GAAP operating... More
